readthroughSign in
CompanyIMRNNasdaqCarlton, Victoria, C3

Immuron Ltd

Immuron develops orally delivered targeted polyclonal antibodies for infectious diseases.

6-KNov 10Latest SEC filing
Oct 23Latest story